Check what?
They have 43 mil cash, plus a 20mil facility from Novaquest( to be used on the Phase 3) which won't be released until the CF303 trial commences.
So they don't have 63 mil available. Since the additional 20mil has not been released yet, and it's also to be spent on the trial, it's not there to help Pharmaxis ease cash burn per quarter.
"The $6m per quarter reflected higher spend on the discovery assets they want to sell off in the near term- it will not be ongoing."
It was actually 6.9 million( 6mil was taking into account further cost cuts), the trouble is most of that is made up of Staffing costs, and costs associated with Bronticol/ Aridol- It's always gong to be high.
"Also patients on Kalydeco still need a nebulizer or other assistance (such as Bronchitol) to clear their lungs. Bronchitol is complementary to Kalydeco and trials are showing the both together deliver great outcomes for patients"
Kalydeco is only used to treat certain mutations( G551D, G1244E, G1349D, G178R, G551S, G970R, S1251N, S1255P, S549N, or S549R), which is only around 5% of the CF population. The trial i'm referring to is Kalydeco in combination with their new compound VX-809( In Patients with a Delta F508 mutation, which accounts for 80% of the EU CF population & 50% of the global) Phase 2 results from were as good as Bronchitol, so there might not be much point in a combination therapy, or insurance plans might not cover it. My point is that if Vertex gain FDA approval this year, then it's going to be very difficult for PXS to compete if they can't gain approval until 2016. It's also going effect Bronchitol sales in the EU.
Add to My Watchlist
What is My Watchlist?
